Arbutus Biopharma (ABUS) Short Interest Ratio & Short Volume → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free ABUS Stock Alerts $2.98 +0.09 (+3.11%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Arbutus Biopharma Short Interest DataCurrent Short Volume5,810,000 sharesPrevious Short Volume5,170,000 sharesChange Vs. Previous Month+12.38%Dollar Volume Sold Short$15.86 millionShort Interest Ratio / Days to Cover4.3Last Record DateApril 30, 2024Outstanding Shares188,720,000 sharesPercentage of Shares Shorted3.08%Today's Trading Volume746,100 sharesAverage Trading Volume1,149,454 sharesToday's Volume Vs. Average65% Short Selling Arbutus Biopharma ? Sign up to receive the latest short interest report for Arbutus Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatABUS Short Interest Over TimeABUS Days to Cover Over TimeABUS Percentage of Float Shorted Over Time Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. Arbutus Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20245,810,000 shares $15.86 million +12.4%N/A4.3 $2.73 4/15/20245,170,000 shares $15.35 million +13.6%N/A3.7 $2.97 3/31/20244,550,000 shares $11.74 million +10.2%N/A3.4 $2.58 3/15/20244,130,000 shares $10.82 million +1.5%N/A4.4 $2.62 2/29/20244,070,000 shares $11.40 million +10.3%N/A4.2 $2.80 2/15/20243,690,000 shares $10.74 million -39.7%N/A3.8 $2.91 Get the Latest News and Ratings for ABUS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. 1/31/20246,120,000 shares $14.50 million -4.8%N/A7.3 $2.37 1/15/20246,430,000 shares $14.85 million +3.4%N/A9.5 $2.31 12/31/20236,220,000 shares $15.55 million +0.5%N/A9.1 $2.50 12/15/20236,190,000 shares $13.87 million +0.2%N/A9.2 $2.24 11/30/20236,180,000 shares $12.67 million -8.2%N/A9.4 $2.05 11/15/20236,730,000 shares $12.38 million +6.7%N/A10.6 $1.84 10/31/20236,310,000 shares $11.55 million +9.4%N/A10.4 $1.83 10/15/20235,770,000 shares $10.73 million -16.1%N/A9.4 $1.86 9/30/20236,880,000 shares $13.97 million +18.6%N/A11.2 $2.03 9/15/20235,800,000 shares $11.83 million +12.0%N/A9.4 $2.04 8/31/20235,180,000 shares $10.52 million +0.8%N/A8.3 $2.03 8/15/20235,140,000 shares $10.23 million +5.1%N/A8.4 $1.99 7/31/20234,890,000 shares $10.61 million +0.8%N/A8.5 $2.17 7/15/20234,850,000 shares $10.82 million -0.8%N/A7.8 $2.23 6/30/20234,890,000 shares $11.25 million +12.7%N/A6.8 $2.30 6/15/20234,340,000 shares $10.59 million +2.1%N/A5.8 $2.44 5/31/20234,250,000 shares $10.58 million -0.9%N/A5.3 $2.49 5/15/20234,290,000 shares $10.98 million +8.3%N/A4.7 $2.56 4/30/20233,960,000 shares $9.94 million -7.0%N/A4.2 $2.51 4/15/20234,260,000 shares $12.23 million -13.9%N/A4.7 $2.87 3/31/20234,950,000 shares $15.00 million +5.5%N/A5.4 $3.03 3/15/20234,690,000 shares $14.21 million +15.8%N/A5 $3.03 2/28/20234,050,000 shares $11.26 million +1.5%N/A4.5 $2.78 2/15/20233,990,000 shares $10.85 million -7.4%N/A4.5 $2.72 1/31/20234,310,000 shares $12.97 million -8.5%N/A4.6 $3.01 1/15/20234,710,000 shares $13.42 million -0.6%N/A4.9 $2.85 12/30/20224,740,000 shares $11.04 million +23.1%N/A4.6 $2.33 12/15/20223,850,000 shares $10.43 million -4.0%N/A4.1 $2.71 11/30/20224,010,000 shares $9.42 million +7.2%N/A4.4 $2.35 11/15/20223,740,000 shares $10.43 million -10.3%N/A4.3 $2.79 10/31/20224,170,000 shares $9.76 million -0.7%N/A5.2 $2.34 10/15/20224,200,000 shares $9.20 million +2.2%N/A5.4 $2.19 9/30/20224,110,000 shares $7.85 million +7.6%N/A5.6 $1.91 9/15/20223,820,000 shares $8.82 million -2.6%N/A4.7 $2.31Shocking $16T Elon Musk Crypto Leak (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. ABUS Short Interest - Frequently Asked Questions What is Arbutus Biopharma's current short interest? Short interest is the volume of Arbutus Biopharma shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 5,810,000 shares of ABUS short. Learn More on Arbutus Biopharma's current short interest. What is a good short interest ratio for Arbutus Biopharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ABUS shares currently have a short interest ratio of 4.0. Learn More on Arbutus Biopharma's short interest ratio. Which institutional investors are shorting Arbutus Biopharma? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Arbutus Biopharma: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Arbutus Biopharma's short interest increasing or decreasing? Arbutus Biopharma saw a increase in short interest in April. As of April 30th, there was short interest totaling 5,810,000 shares, an increase of 12.4% from the previous total of 5,170,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Arbutus Biopharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Arbutus Biopharma: IGM Biosciences, Inc. (29.87%), Aerovate Therapeutics, Inc. (10.43%), Y-mAbs Therapeutics, Inc. (7.47%), Applied Therapeutics, Inc. (3.91%), KalVista Pharmaceuticals, Inc. (13.13%), Altimmune, Inc. (31.47%), Verve Therapeutics, Inc. (30.19%), SIGA Technologies, Inc. (13.53%), Astria Therapeutics, Inc. (10.24%), COMPASS Pathways plc (4.99%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Arbutus Biopharma stock? Short selling ABUS is an investing strategy that aims to generate trading profit from Arbutus Biopharma as its price is falling. ABUS shares are trading up $0.09 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Arbutus Biopharma? A short squeeze for Arbutus Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ABUS, which in turn drives the price of the stock up even further. How often is Arbutus Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ABUS, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: IGMS Short Squeeze AVTE Short Squeeze YMAB Short Squeeze APLT Short Squeeze KALV Short Squeeze ALT Short Squeeze VERV Short Squeeze SIGA Short Squeeze ATXS Short Squeeze CMPS Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ABUS) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersMost important medical advance in 100 yearsThe Oxford ClubDems have chosen Biden replacement?Paradigm Press